(RTTNews) - Immuron (IMRN) has submitted an Investigational New Drug application to the FDA for clinical development of IMM-529. The company is proposing the development of IMM-529 for treatment of Clostridioides difficile infection and prevention of recurrent CDI.
The company plans to initiate a Phase 2 trial for IMM-529 in individuals with Clostridioides difficile infection during the first half of 2026. IMM-529 specifically targets Toxin B, the spores, and the surface layer proteins of the vegetative cells.
Shares of Immuron are up 8% in pre-market trade on Wednesday.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Why Immuron Is Rising In Pre-market?
Published 1 month ago
Oct 8, 2025 at 10:16 AM
Positive
Auto